The current approach and the treatment of adolescents and young adults with acute lymphoblastic leukemia

Borivoj Sekulić
{"title":"The current approach and the treatment of adolescents and young adults with acute lymphoblastic leukemia","authors":"Borivoj Sekulić","doi":"10.2298/mpns22s1015s","DOIUrl":null,"url":null,"abstract":"Introduction. The treatment outcome of adolescents and young adults with acute lymphoblastic leukemia is much poorer in contrast to pediatric patients. By changing the concept of the treatment for patients who are adolescents and young adults with acute lymphoblastic leukemia, especially with the use of pediatric regimens, significant improvement in survival has been made (current 5-year survival rate goes up to 70%). Contributing factors for different outcomes between children and adolescents and young adults with acute lymphoblastic leukemia. Beside the differences between pediatric and adult protocols, there are several factors which can explain the different outcomes between these groups of patients with acute lymphoblastic leukemia. One of the main factors is different biology of the leukemias and, on the other side, lower accrual rates in clinical trials in adolescents and young adults and their specific psychosocial factors, like poor compliance with the treatment and missed appointments. Current treatment and novel approaches in the treatment of adolescents and young adults with acute lymphoblastic leukemia. Current treatment approach to the adolescent and young adults with acute lymphoblastic leukemia is based on the pediatric protocols with the risk-adapted strategy, which depends primarily on the cytogenetics and postinduction minimal/measurable residual disease. The main goal of the novel treatment, especially with the use of targeted therapy and innovative immunotherapies incorporated in the pediatric protocols, is to achieve a deep and durable leukemia-free survival. To transplant or not to transplant adolescents and young adults with acute lymphoblastic leukemia is still a matter of debate, particularly in the era of pediatric regimens and the new sequence algorithm with the upfront use of novel drugs. Conclusion. Adolescent and young adult patients with acute lymphoblastic leukemia should be treated in specialized centers by an experienced multidisciplinary team with close attention to their particular needs.","PeriodicalId":87940,"journal":{"name":"Calcutta medical review","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Calcutta medical review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2298/mpns22s1015s","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. The treatment outcome of adolescents and young adults with acute lymphoblastic leukemia is much poorer in contrast to pediatric patients. By changing the concept of the treatment for patients who are adolescents and young adults with acute lymphoblastic leukemia, especially with the use of pediatric regimens, significant improvement in survival has been made (current 5-year survival rate goes up to 70%). Contributing factors for different outcomes between children and adolescents and young adults with acute lymphoblastic leukemia. Beside the differences between pediatric and adult protocols, there are several factors which can explain the different outcomes between these groups of patients with acute lymphoblastic leukemia. One of the main factors is different biology of the leukemias and, on the other side, lower accrual rates in clinical trials in adolescents and young adults and their specific psychosocial factors, like poor compliance with the treatment and missed appointments. Current treatment and novel approaches in the treatment of adolescents and young adults with acute lymphoblastic leukemia. Current treatment approach to the adolescent and young adults with acute lymphoblastic leukemia is based on the pediatric protocols with the risk-adapted strategy, which depends primarily on the cytogenetics and postinduction minimal/measurable residual disease. The main goal of the novel treatment, especially with the use of targeted therapy and innovative immunotherapies incorporated in the pediatric protocols, is to achieve a deep and durable leukemia-free survival. To transplant or not to transplant adolescents and young adults with acute lymphoblastic leukemia is still a matter of debate, particularly in the era of pediatric regimens and the new sequence algorithm with the upfront use of novel drugs. Conclusion. Adolescent and young adult patients with acute lymphoblastic leukemia should be treated in specialized centers by an experienced multidisciplinary team with close attention to their particular needs.
目前的方法和治疗青少年和青壮年急性淋巴细胞白血病
介绍。与儿科患者相比,青少年和青壮年急性淋巴细胞白血病的治疗结果要差得多。通过改变青少年和青壮年急性淋巴细胞白血病患者的治疗理念,特别是使用儿科方案,生存率显著提高(目前5年生存率高达70%)。儿童、青少年和青年急性淋巴细胞白血病不同预后的影响因素。除了儿童和成人治疗方案之间的差异,还有几个因素可以解释急性淋巴细胞白血病这两组患者之间不同的结果。其中一个主要因素是白血病的不同生物学特性,另一方面,在青少年和年轻人的临床试验中,较低的应计率以及他们特定的社会心理因素,如治疗依从性差和错过预约。当前治疗和新方法在治疗青少年和青年急性淋巴细胞白血病。目前对青少年和青年急性淋巴细胞白血病的治疗方法是基于风险适应策略的儿科方案,主要取决于细胞遗传学和诱导后最小/可测量的残留疾病。这种新疗法的主要目标,特别是在儿科方案中结合靶向治疗和创新免疫疗法的使用,是实现深度和持久的无白血病生存。对于患有急性淋巴细胞白血病的青少年和年轻人来说,移植或不移植仍然是一个有争议的问题,特别是在儿科治疗方案和新序列算法与新药物的前期使用的时代。结论。患有急性淋巴细胞白血病的青少年和年轻成人患者应在专业中心由经验丰富的多学科团队进行治疗,并密切关注他们的特殊需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信